Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Breast and other cancer dormancy as a therapeutic endpoint: speculative recombinant T cell receptor ligand (RTL) adjuvant therapy worth considering?

Figure 1

Strong medicine. The human T cell, a multitasking agent in the immune system, is normally activated only when two receptors are stimulated (left). But the "superagonist" used in a London clinical trial can activate T cells by stimulating a single receptor (right). Credit: (illustration) C. Bickel/Science. Reproduced with permission from Marshall E. Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery. Science 2006;311(5768):1688-9.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us